Etiology and treatment of adrenoleukodystrophy: new insights from Drosophila
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Adrenoleukodystrophy (ALD) is a fatal progressive neurodegenerative disorder affecting brain white matter. The most common form of ALD is X-linked (X-ALD) and results from mutation of the ABCD1-encoded very long chain fatty acid (VLCFA) transporter. X-ALD is clinically heterogeneous, with the cerebral form being the most severe. Diagnosed in boys usually between the ages of 4 and 8, cerebral X-ALD symptoms progress rapidly (in as little as two years) through declines in cognition, learning, and behavior, to paralysis and ultimately to a vegetative state and death. Currently, there are no good treatments for X-ALD. Here we exploit the Drosophila bubblegum (bgm) double bubble (dbb) model of neurometabolic disease to expand diagnostic power and therapeutic potential for adrenoleukodystrophy. We show that loss of the Drosophila long/very long chain acyl-CoA synthetase genes bgm and/or dbb is indistinguishable from loss of the Drosophila ABC transporter gene dABCD1. Shared loss-of-function phenotypes for synthetase and transporter mutants point to a lipid metabolic pathway association with ALD-like neurodegenerative disease in Drosophila; a pathway association that has yet to be established in humans. We also show that manipulation of environment increases the severity of neurodegeneration in bgm and dbb flies, adding even further to a suite of new candidate ALD disease-causing genes and pathways in humans. Finally, we show that it is a lack of lipid metabolic pathway product and not (as commonly thought) an accumulation of pathway precursor that is causative of neurometabolic disease: addition of medium chain fatty acids to the diet of bgm or dbb flies prevents the onset of neurodegeneration. Taken together, our data provide new foundations both for diagnosing adrenoleukodystrophy and for designing effective, mechanism-based treatment protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 2×
“Moreover, some recipients of hematopoietic stem cell gene therapy show improvement in neurological symptoms despite plasma VLCFA concentrations remaining significantly high (Cartier et al., 2009).”
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 2×
“Adrenoleukodystrophy (ALD) is a neurodegenerative disorder associated with mutation of the peroxisomal ABC transporter protein ALDP (adrenoleukodystrophy protein) that is encoded by the X chromosome locus ABCD1 (Mosser et al., 1993) .”
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604 · cited 5×
“Although ABCD1 , the gene responsible for the most common form of ALD (X-ALD), has been cloned, the etiology of the disease has remained elusive and there are still no satisfactory treatments or cures (for review see Gordon et al., 2014).”
InfluentialEngelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
A Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291101 · Cited by 242 · cited 2×
“Another touted therapy called Lorenzo ’ s oil is thought to target accumulated VLCFAs but remains a controversial option, with most agreeing that it is ineffective (Aubourg et al., 1993; Berger et al., 2010; Gordon et al., 2014).”
Kobayashi, T., Shinnoh, N., Kondo, A., & Yamada, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6340 · Cited by 197
Hein, S., Schonfeld, P., Kahlert, S., & Reiser, G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn066 · Cited by 180 · cited 1×
“In humans, evidence for accumulating FAs as being causative of disease comes primarily from tissue culture studies, where accumulating FAs can lead to cell death (Hein et al., 2008; Reiser et al., 2006; Ulloth et al., 2003).”
Retinal very long-chain PUFAs: new insights from studies on ELOVL4 protein
Agbaga, M.-P., Mandal, M. N. A., & Anderson, R. E. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r005025 · Cited by 167 · cited 1×
“Interestingly, in humans, the longest VLCFA species are found only in tissues expressing elongases, namely the retina, brain and testis, all three of which are key tissues affected in ALD (Agbaga et al., 2010; Ahmad et al., 2009).”
Dubey, P., Raymond, G. V., Moser, A. B., Kharkar, S., Bezman, L., & Moser, H. W. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.10.067 · Cited by 145 · cited 1×
“…ABCD1 hemizygotes showing that, although all individuals harboring mutant alleles of ABCD1 exhibit similar significant increases in their circulating VLCFA levels, these correlate with neither the development of disease nor the timing of disease onset (Dubey et al., 2005; Raymond et al., 1999).”
Berger, J., Molzer, B., Fae, I., & Bernheimer, H. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2855 · Cited by 126
Cited by
Loss-or gain-of-function mutations in ACOX1 cause axonal loss via different mechanisms
Chung, H.-L., Wangler, M. F., Marcogliese, P. C., Jo, J., Ravenscroft, T. A., Zuo, Z., Duraine, L., Sadeghzadeh, S., Li-Kroeger, D., Schmidt, R. E., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.02.021 · Cited by 154
Peroxisomal ABC Transporters: An Update
Tawbeh, A., Gondcaille, C., Trompier, D., & Savary, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116093 · Cited by 68
Bülow, M. H., Parsons, B. D., & Di Cara, F. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-60204-8_11 · Cited by 8
Manor, J., Jangam, S. V., Chung, H.-L., Bhagwat, P., Andrews, J., Chester, H., Kondo, S., Srivastav, S., Botas, J., Moser, A. B., et al. (2024) · doi:10.1101/2024.09.23.614586 · Cited by 2
Metadata
- Authors
- Gordon, H. B., Valdez, L., & Letsou, A.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2018-01-01
- Volume
- 11
- Issue
- 6
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2799937650
- Cited by
- 19
- References
- 14
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Etiology and treatment of adrenoleukodystrophy: new insights from Drosophila. https://app.cochat.ai/papers/10.1242/dmm.031286
- The paper
- Gordon, H. B., Valdez, L., & Letsou, A. (2018). Etiology and treatment of adrenoleukodystrophy: new insights from Drosophila. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.031286
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.